Items Tagged ‘cytaribine-dauorubicin’

January 28th, 2015

CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients


The U. S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigational drug CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. Acute myeloid leukemia (AML) is a cancer of the bone marrow (spongy portion found in the middle of bones) and blood […]

View full entry

Tags: Acute Myeloid Leukemia, AML, cpx-351, cytaribine-dauorubicin, fda, Leukemia, News